$BMRA

MOATAZEDI DAVID purchased $16K of BMRA

MOATAZEDI DAVID purchased 10,000 shares of BIOMERICA INC (BMRA) at $1.60 on 2026-08-26.

Original reporting
SEC EDGAR · MOATAZEDI DAVID
Published Aug 27, 2026, 9:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 10:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BMRA
Neutral
high confidence
Mentioned
$BMRA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BMRANeutralLow
01

Why it matters

The director's purchase adds modest confidence in the company's outlook but is unlikely to affect price.

02

Market read

Routine insider purchase with limited trading relevance.

03

What to watch

Potential upcoming clinical trial milestones could make insider activity more meaningful.

Relevance 4/10Novelty 5/10Timing: same-day filing

Background

Form 4 filings disclose insider transactions; this is the first public report of this purchase.

Company-level read

Ticker impact

$BMRANeutralHigh confidence
Context

Director Moatazedi David purchased 10,000 shares of Biomerca Inc at $1.60 each, increasing his holding to 40,625 shares.

Expected impact

minimal impact, price likely to stay within current range

Evidence & confidence

The transaction size ($16k) is modest relative to typical trading volume; director ownership already sizable.

Market effects

None; the purchase does not signal broader sector trends.

None; limited to Biomerca shareholders.

None; micro‑cap insider activity has negligible global effect.

Counterpoint

Even small insider buys can precede larger strategic moves; monitor for future filings.

Key entities

  • Biomerca Inc

    US‑listed biotech company (ticker BMRA).

  • Moatazedi David

    Director of Biomerca Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BMRAMedAI 9/10

Biomerica Wins $1.75M Contract to Develop Diagnostic Tests

Biomerica Inc. said it was selected for a $1.75 million master services agreement with an undisclosed life sciences company to develop in vitro diagnostic assays. The three-year work will be performed at Biomerica’s Irvine facility, according to the company. Biomerica said the initial fees provide near-term revenue visibility. Shares fell 2.2% to $2.40.